These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11209636)

  • 1. 10% hydroxyethyl starch for plasma expansion in the treatment of severe ovarian hyperstimulation syndrome. A case report.
    Rabinerson D; Ben Rafael Z; Keslin J; Zolotarsky V; Dekel A
    J Reprod Med; 2001 Jan; 46(1):68-70. PubMed ID: 11209636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compressive pleural effusion after ovarian hyperstimulation syndrome--a case report and review.
    Beji O; Brahmi N; Thabet H; Mokline A; Abidi N; Blel Y; Kouraichi N; Amamou M
    Fertil Steril; 2008 Jun; 89(6):1826.e1-3. PubMed ID: 17761176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Severe ovarian hyperstimulation syndrome and tubal pregnancy after in vitro fertilization].
    Nawroth F; Kissing K
    Zentralbl Gynakol; 1998; 120(7):347-9. PubMed ID: 9703658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Research on the protocol of limited ovarian stimulation to prevent ovarian hyperstimulation syndrome].
    Zhu YM; Gao HJ; He RH; Huang HF
    Zhonghua Fu Chan Ke Za Zhi; 2006 Nov; 41(11):740-4. PubMed ID: 17327030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of severe ovarian hyperstimulation syndrome after inadvertent stimulation with a gonadotropin-releasing hormone agonist and human menopausal gonadotropin in a pre-existing early pregnancy.
    Zech NH; Netzbandt P; Zech H
    Fertil Steril; 2005 Dec; 84(6):1745. PubMed ID: 16359980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic dysfunction associated with moderate ovarian hyperstimulation syndrome. A case report.
    Elter K; Scoccia B; Nelson LR
    J Reprod Med; 2001 Aug; 46(8):765-8. PubMed ID: 11547654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Massive vulvar edema in ovarian hyperstimulation syndrome. A case report.
    Coccia ME; Bracco GL; Cattaneo A; Scarselli G
    J Reprod Med; 1995 Sep; 40(9):659-60. PubMed ID: 8576885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicted value of renin activity in a woman who had severe ovarian hyperstimulation syndrome with internal jugular vein thrombosis.
    Chang FW; Chan CC; Yin CS; Wu GJ
    Fertil Steril; 2004 Oct; 82(4):937-9. PubMed ID: 15482774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver dysfunction in severe ovarian hyperstimulation syndrome.
    Obrzut B; Kuczyński W; Grygoruk C; Putowski L; Kluz S; Skret A
    Gynecol Endocrinol; 2005 Jul; 21(1):45-9. PubMed ID: 16048801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on ovarian hyperstimulation syndrome: part 2--clinical signs and treatment.
    Binder H; Dittrich R; Einhaust F; Krieg J; Müller A; Strauss R; Beckmann MW; Cupisti S
    Int J Fertil Womens Med; 2007; 52(2-3):69-81. PubMed ID: 18320864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles.
    Hernández ER; Gómez-Palomares JL; Ricciarelli E
    Fertil Steril; 2009 Apr; 91(4 Suppl):1358-61. PubMed ID: 18555236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH agonist administration after embryo transfer, in long protocol stimulated cycles, prevents ovarian hyperstimulation syndrome. A report of five cases.
    Nikolettos N; Asimakopoulos B; Simopoulou M; al-Hasani S
    In Vivo; 2003; 17(6):655-8. PubMed ID: 14758735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The optimal length of 'coasting protocol' in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization.
    Nardo LG; Cheema P; Gelbaya TA; Horne G; Fitzgerald CT; Pease EH; Brison DR; Lieberman BA
    Hum Fertil (Camb); 2006 Sep; 9(3):175-80. PubMed ID: 17008270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical ovarian hyperstimulation syndrome in a coasted in-vitro fertilization patient.
    Tortoriello DV; McGovern PG; Colon JM; Loughlin J; Santoro N
    Hum Reprod; 1998 Nov; 13(11):3005-8. PubMed ID: 9853846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of ovarian hyperstimulation syndrome.
    Aboulghar M
    Semin Reprod Med; 2010 Nov; 28(6):532-9. PubMed ID: 21082512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ovarian overstimulation syndrome: problem of intensive care].
    Korneeva IE; Veriaeva NA; Gel'fand BR; Churadze BT
    Anesteziol Reanimatol; 2007; (6):59-63. PubMed ID: 18326263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombosis post ovarian hyperstimulation.
    Chipwete SE; Bugren S; Rafla N
    Fertil Steril; 2009 May; 91(5):1956.e13-4. PubMed ID: 19261273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme.
    Graf MA; Fischer R; Naether OG; Baukloh V; Tafel J; Nückel M
    Hum Reprod; 1997 Dec; 12(12):2599-602. PubMed ID: 9455820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.